| Added by | amaraver |
|---|---|
| Group name | EquipeAM |
| Item Type | Journal Article |
| Title | Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design |
| Creator | Garrido et al. |
| Author | Pilar Garrido |
| Author | Jean-Louis Pujol |
| Author | Edward S. Kim |
| Author | Jay M. Lee |
| Author | Masahiro Tsuboi |
| Author | Ana Gómez-Rueda |
| Author | Amparo Benito |
| Author | Nicolas Moreno |
| Author | Luis Gorospe |
| Author | Tuochuan Dong |
| Author | Cecile Blin |
| Author | Vanessa Rodrik-Outmezguine |
| Author | Vanessa Q. Passos |
| Author | Tony Sk Mok |
| Abstract | Canakinumab is a human IgG? monoclonal antibody, with high affinity and specificity for IL-1?. The Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) trial, evaluating canakinumab for cardiovascular disease, provided the first signal of the potential of IL-1? inhibition on lung cancer incidence reduction. Here, we describe the rationale and design for CANOPY-N, a randomized Phase II trial evaluating IL-1? inhibition with or without immune checkpoint inhibition as neoadjuvant treatment in patients with non-small-cell lung cancer. Patients with stage IB to IIIA non-small-cell lung cancer eligible for complete resection will receive canakinumab or pembrolizumab as monotherapy, or in combination. The primary end point is major pathological response by central review; secondary end points include overall response rate, major pathological response (local review), surgical feasibility rate and pharmacokinetics. Clinical trial registration: NCT03968419 (ClinicalTrials.gov). |
| Publication | Future Oncology (London, England) |
| Volume | 17 |
| Issue | 12 |
| Pages | 1459-1472 |
| Date | 2021-04 |
| Journal Abbr | Future Oncol |
| Language | eng |
| DOI | 10.2217/fon-2020-1098 |
| ISSN | 1744-8301 |
| Short Title | Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer |
| Library Catalog | PubMed |
| Extra | PMID: 33648347 |
| Tags | Adolescent, Adult, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, canakinumab, CANOPY, Carcinoma, Non-Small-Cell Lung, clinic, Clinical Trials, Phase II as Topic, Female, Humans, Interleukin-1beta, Lung, Lung Neoplasms, major pathological response, Male, MPR, neoadjuvant, Neoadjuvant Therapy, Neoplasm Staging, non-small-cell lung cancer, Pneumonectomy, Programmed Cell Death 1 Receptor, Randomized Controlled Trials as Topic, resection, Young Adult |
| Date Added | 2022/08/31 - 14:27:24 |
| Date Modified | 2022/08/31 - 14:27:33 |
| Notes and Attachments | Full Text (Attachment) PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
